The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials
First-generation anit-SARS-CoV-2 vaccines were highly successful. They rapidly met an unforeseen emergency need, saved millions of lives, and simultaneously eased the burden on healthcare systems worldwide. The first-generation vaccines, however, focused too narrowly on antibody-based immunity as th...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.923106/full |
| _version_ | 1798031852825477120 |
|---|---|
| author | Robert L. Murphy Robert L. Murphy Eustache Paramithiotis Scott Sugden Todd Chermak Bruce Lambert Damien Montamat-Sicotte John Mattison Steve Steinhubl |
| author_facet | Robert L. Murphy Robert L. Murphy Eustache Paramithiotis Scott Sugden Todd Chermak Bruce Lambert Damien Montamat-Sicotte John Mattison Steve Steinhubl |
| author_sort | Robert L. Murphy |
| collection | DOAJ |
| description | First-generation anit-SARS-CoV-2 vaccines were highly successful. They rapidly met an unforeseen emergency need, saved millions of lives, and simultaneously eased the burden on healthcare systems worldwide. The first-generation vaccines, however, focused too narrowly on antibody-based immunity as the sole marker of vaccine trial success, resulting in large knowledge gaps about waning vaccine protection, lack of vaccine robustness to viral mutation, and lack of efficacy in immunocompromised populations. Detailed reviews of first-generation vaccines, including their mode of action and geographical distribution, have been published elsewhere. Second-generation clinical trials must address these gaps by evaluating a broader range of immune markers, including those representing cell-mediated immunity, to ensure the most protective and long-lasting vaccines are brought to market. |
| first_indexed | 2024-04-11T20:04:19Z |
| format | Article |
| id | doaj.art-134f6bfbc1ec429c92ca0123e403b85b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T20:04:19Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-134f6bfbc1ec429c92ca0123e403b85b2022-12-22T04:05:22ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.923106923106The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trialsRobert L. Murphy0Robert L. Murphy1Eustache Paramithiotis2Scott Sugden3Todd Chermak4Bruce Lambert5Damien Montamat-Sicotte6John Mattison7Steve Steinhubl8Northwestern University, Evanston, IL, United StatesFeinberg School of Medicine, Northwestern University, Chicago, IL, United StatesCellCarta, Montreal, QC, CanadaCellCarta, Montreal, QC, CanadaCellCarta, Montreal, QC, CanadaNorthwestern University, Evanston, IL, United StatesCellCarta, Montreal, QC, CanadaArsenal Capital, New York City, NY, United StatesphysIQ, Chicago, IL, United StatesFirst-generation anit-SARS-CoV-2 vaccines were highly successful. They rapidly met an unforeseen emergency need, saved millions of lives, and simultaneously eased the burden on healthcare systems worldwide. The first-generation vaccines, however, focused too narrowly on antibody-based immunity as the sole marker of vaccine trial success, resulting in large knowledge gaps about waning vaccine protection, lack of vaccine robustness to viral mutation, and lack of efficacy in immunocompromised populations. Detailed reviews of first-generation vaccines, including their mode of action and geographical distribution, have been published elsewhere. Second-generation clinical trials must address these gaps by evaluating a broader range of immune markers, including those representing cell-mediated immunity, to ensure the most protective and long-lasting vaccines are brought to market.https://www.frontiersin.org/articles/10.3389/fimmu.2022.923106/fullimmune profilingSARS – CoV – 2vaccine trial designvaccinesCOVID - 19cellular immunity |
| spellingShingle | Robert L. Murphy Robert L. Murphy Eustache Paramithiotis Scott Sugden Todd Chermak Bruce Lambert Damien Montamat-Sicotte John Mattison Steve Steinhubl The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials Frontiers in Immunology immune profiling SARS – CoV – 2 vaccine trial design vaccines COVID - 19 cellular immunity |
| title | The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials |
| title_full | The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials |
| title_fullStr | The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials |
| title_full_unstemmed | The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials |
| title_short | The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials |
| title_sort | need for more holistic immune profiling in next generation sars cov 2 vaccine trials |
| topic | immune profiling SARS – CoV – 2 vaccine trial design vaccines COVID - 19 cellular immunity |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.923106/full |
| work_keys_str_mv | AT robertlmurphy theneedformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT robertlmurphy theneedformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT eustacheparamithiotis theneedformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT scottsugden theneedformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT toddchermak theneedformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT brucelambert theneedformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT damienmontamatsicotte theneedformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT johnmattison theneedformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT stevesteinhubl theneedformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT robertlmurphy needformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT robertlmurphy needformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT eustacheparamithiotis needformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT scottsugden needformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT toddchermak needformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT brucelambert needformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT damienmontamatsicotte needformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT johnmattison needformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials AT stevesteinhubl needformoreholisticimmuneprofilinginnextgenerationsarscov2vaccinetrials |